239 related articles for article (PubMed ID: 23658392)
1. Evaluation of immunogenicity and efficacy of anthrax vaccine adsorbed for postexposure prophylaxis.
Ionin B; Hopkins RJ; Pleune B; Sivko GS; Reid FM; Clement KH; Rudge TL; Stark GV; Innes A; Sari S; Guina T; Howard C; Smith J; Swoboda ML; Vert-Wong E; Johnson V; Nabors GS; Skiadopoulos MH
Clin Vaccine Immunol; 2013 Jul; 20(7):1016-26. PubMed ID: 23658392
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of early immune response-survival relationship in cynomolgus macaques after Anthrax Vaccine Adsorbed vaccination and Bacillus anthracis spore challenge.
Sivko GS; Stark GV; Tordoff KP; Taylor KL; Glaze E; VanRaden M; Schiffer JM; Hewitt JA; Quinn CP; Nuzum EO
Vaccine; 2016 Dec; 34(51):6518-6528. PubMed ID: 27155494
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and immunogenicity of single-dose AdVAV intranasal anthrax vaccine compared to anthrax vaccine absorbed in an aerosolized spore rabbit challenge model.
Krishnan V; Andersen BH; Shoemaker C; Sivko GS; Tordoff KP; Stark GV; Zhang J; Feng T; Duchars M; Roberts MS
Clin Vaccine Immunol; 2015 Apr; 22(4):430-9. PubMed ID: 25673303
[TBL] [Abstract][Full Text] [Related]
4. Recombinant protective antigen anthrax vaccine improves survival when administered as a postexposure prophylaxis countermeasure with antibiotic in the New Zealand white rabbit model of inhalation anthrax.
Leffel EK; Bourdage JS; Williamson ED; Duchars M; Fuerst TR; Fusco PC
Clin Vaccine Immunol; 2012 Aug; 19(8):1158-64. PubMed ID: 22695155
[TBL] [Abstract][Full Text] [Related]
5. Correlation between anthrax lethal toxin neutralizing antibody levels and survival in guinea pigs and nonhuman primates vaccinated with the AV7909 anthrax vaccine candidate.
Savransky V; Shearer JD; Gainey MR; Sanford DC; Sivko GS; Stark GV; Li N; Ionin B; Lacy MJ; Skiadopoulos MH
Vaccine; 2017 Sep; 35(37):4952-4959. PubMed ID: 28774566
[TBL] [Abstract][Full Text] [Related]
6. Cross-species prediction of human survival probabilities for accelerated anthrax vaccine absorbed (AVA) regimens and the potential for vaccine and antibiotic dose sparing.
Stark GV; Sivko GS; VanRaden M; Schiffer J; Taylor KL; Hewitt JA; Quinn CP; Nuzum EO
Vaccine; 2016 Dec; 34(51):6512-6517. PubMed ID: 27558619
[TBL] [Abstract][Full Text] [Related]
7. Phase 3 trial evaluating the immunogenicity and safety of a three-dose BioThrax® regimen for post-exposure prophylaxis in healthy adults.
Hopkins RJ; Howard C; Hunter-Stitt E; Kaptur PE; Pleune B; Muse D; Sheldon E; Davis M; Strout C; Vert-Wong K
Vaccine; 2014 Apr; 32(19):2217-24. PubMed ID: 24613523
[TBL] [Abstract][Full Text] [Related]
8. Vaccination of rhesus macaques with the anthrax vaccine adsorbed vaccine produces a serum antibody response that effectively neutralizes receptor-bound protective antigen in vitro.
Clement KH; Rudge TL; Mayfield HJ; Carlton LA; Hester A; Niemuth NA; Sabourin CL; Brys AM; Quinn CP
Clin Vaccine Immunol; 2010 Nov; 17(11):1753-62. PubMed ID: 20739500
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of the AV7909 anthrax vaccine candidate in guinea pigs and nonhuman primates following two immunizations two weeks apart.
Shearer JD; Henning L; Sanford DC; Li N; Skiadopoulos MH; Reece JJ; Ionin B; Savransky V
Vaccine; 2021 Jan; 39(1):1-5. PubMed ID: 33199078
[TBL] [Abstract][Full Text] [Related]
10. Randomized, double-blind, active-controlled study evaluating the safety and immunogenicity of three vaccination schedules and two dose levels of AV7909 vaccine for anthrax post-exposure prophylaxis in healthy adults.
Hopkins RJ; Kalsi G; Montalvo-Lugo VM; Sharma M; Wu Y; Muse DD; Sheldon EA; Hampel FC; Lemiale L
Vaccine; 2016 Apr; 34(18):2096-105. PubMed ID: 26979136
[TBL] [Abstract][Full Text] [Related]
11. A three-dose intramuscular injection schedule of anthrax vaccine adsorbed generates sustained humoral and cellular immune responses to protective antigen and provides long-term protection against inhalation anthrax in rhesus macaques.
Quinn CP; Sabourin CL; Niemuth NA; Li H; Semenova VA; Rudge TL; Mayfield HJ; Schiffer J; Mittler RS; Ibegbu CC; Wrammert J; Ahmed R; Brys AM; Hunt RE; Levesque D; Estep JE; Barnewall RE; Robinson DM; Plikaytis BD; Marano N;
Clin Vaccine Immunol; 2012 Nov; 19(11):1730-45. PubMed ID: 22933399
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of a plasmid DNA-based anthrax vaccine in rabbits, nonhuman primates and healthy adults.
Keitel WA; Treanor JJ; El Sahly HM; Evans TG; Kopper S; Whitlow V; Selinsky C; Kaslow DC; Rolland A; Smith LR; Lalor PA
Hum Vaccin; 2009 Aug; 5(8):536-44. PubMed ID: 19458488
[TBL] [Abstract][Full Text] [Related]
13. Comparative immunogenicity and efficacy of thermostable (lyophilized) and liquid formulation of anthrax vaccine candidate AV7909.
Autumn Smiley M; Sanford DC; Triplett CA; Callahan D; Frolov V; Look J; Ruiz C; Reece JJ; Miles A; Ruiz E; Ionin B; Shearer JD; Savransky V
Vaccine; 2019 Oct; 37(43):6356-6361. PubMed ID: 31530467
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of intravenous anthrax immune globulin for treatment of inhalation anthrax.
Mytle N; Hopkins RJ; Malkevich NV; Basu S; Meister GT; Sanford DC; Comer JE; Van Zandt KE; Al-Ibrahim M; Kramer WG; Howard C; Daczkowski N; Chakrabarti AC; Ionin B; Nabors GS; Skiadopoulos MH
Antimicrob Agents Chemother; 2013 Nov; 57(11):5684-92. PubMed ID: 23979731
[TBL] [Abstract][Full Text] [Related]
15. Anthrax vaccine antigen-adjuvant formulations completely protect New Zealand white rabbits against challenge with Bacillus anthracis Ames strain spores.
Peachman KK; Li Q; Matyas GR; Shivachandra SB; Lovchik J; Lyons RC; Alving CR; Rao VB; Rao M
Clin Vaccine Immunol; 2012 Jan; 19(1):11-6. PubMed ID: 22089245
[TBL] [Abstract][Full Text] [Related]
16. A cationic lipid-formulated plasmid DNA vaccine confers sustained antibody-mediated protection against aerosolized anthrax spores.
Hermanson G; Whitlow V; Parker S; Tonsky K; Rusalov D; Ferrari M; Lalor P; Komai M; Mere R; Bell M; Brenneman K; Mateczun A; Evans T; Kaslow D; Galloway D; Hobart P
Proc Natl Acad Sci U S A; 2004 Sep; 101(37):13601-6. PubMed ID: 15342913
[TBL] [Abstract][Full Text] [Related]
17. Marked enhancement of the immune response to BioThrax® (Anthrax Vaccine Adsorbed) by the TLR9 agonist CPG 7909 in healthy volunteers.
Rynkiewicz D; Rathkopf M; Sim I; Waytes AT; Hopkins RJ; Giri L; DeMuria D; Ransom J; Quinn J; Nabors GS; Nielsen CJ
Vaccine; 2011 Aug; 29(37):6313-20. PubMed ID: 21624418
[TBL] [Abstract][Full Text] [Related]
18. Use of Anthrax Vaccine in the United States: Recommendations of the Advisory Committee on Immunization Practices, 2019.
Bower WA; Schiffer J; Atmar RL; Keitel WA; Friedlander AM; Liu L; Yu Y; Stephens DS; Quinn CP; Hendricks K;
MMWR Recomm Rep; 2019 Dec; 68(4):1-14. PubMed ID: 31834290
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive analysis and selection of anthrax vaccine adsorbed immune correlates of protection in rhesus macaques.
Chen L; Schiffer JM; Dalton S; Sabourin CL; Niemuth NA; Plikaytis BD; Quinn CP
Clin Vaccine Immunol; 2014 Nov; 21(11):1512-20. PubMed ID: 25185577
[TBL] [Abstract][Full Text] [Related]
20. Recombinant vaccine displaying the loop-neutralizing determinant from protective antigen completely protects rabbits from experimental inhalation anthrax.
Oscherwitz J; Yu F; Jacobs JL; Cease KB
Clin Vaccine Immunol; 2013 Mar; 20(3):341-9. PubMed ID: 23283638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
